China
Africa
Explore chapters and articles related to this topic
Sulconazole
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Sulconazole is a broad-spectrum imidazole antifungal agent with some antibacterial activity. It is used for the topical treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis and for the treatment of tinea (pityriasis) versicolor. Sulconazole has not been proven effective in treating tinea pedis (athlete’s foot).
Topical Azoles
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Joanne L. Sharp, Michael A. Pfaller
Comparative studies of sulconazole with other imidazole derivatives in the treatment of superficial dermatomycoses revealed mycologic eradication rates of 72–100%. Sulconazole nitrate 1% cream applied twice daily for 3 weeks is an effective treatment for cutaneous candidiasis. The overall clinical and mycologic cure rate was 96% compared with 10% for placebo (Tanenbaum et al., 1983). In one study, sulconazole nitrate 1% cream applied twice daily for 14 days to patients with pyoderma caused by Streptococcus pyogenes and Staphylococcus spp. was extremely effective, with microbial eradication in 100% of patients by day 7 of treatment and rapid clinical resolution (Nolting and Strauss, 1988).
Miconazole for the treatment of vulvovaginal candidiasis. In vitro, in vivo and clinical results. Review of the literature
Published in Journal of Obstetrics and Gynaecology, 2023
Pedro Antonio Regidor, Manopchai Thamkhantho, Chenchit Chayachinda, Santiago Palacios
Of the drugs now on the market in the United States, clotrimazole, miconazole, ketoconazole, econazole, butoconazole, oxiconazole, sertaconazole and sulconazole are imidazoles while terconazole, itraconazole, fluconazole, voriconazole and posaconazole are triazoles (Brunton 2011).
Nanoemulsion-based dosage forms for the transdermal drug delivery applications: A review of recent advances
Published in Expert Opinion on Drug Delivery, 2022
Ankita Roy, Kumar Nishchaya, Vineet Kumar Rai
Systemic fungal infections continue to appear as life-threatening conditions. Noteworthy improvements have been made in treating such conditions utilizing some promising drugs like fluconazole and itraconazole. However, these conditions pose several problems like clinical resistance, microbiological resistance, the emergence of new pathogens, and the involvement of more immunocompromised patients. Recent developments in the delivery of anti-fungal agents have gained momentum. Itraconazole is a triazole derivative with a broad-spectrum antifungal activity. It restricts the synthesis of the fungal cell membrane component ergosterol (helps in cell growth) [68] however had limited utility in treating systemic fungal infections, specifically against onychomycosis. Sampathi et al. in 2018 formulated its nanoemulgel of transdermal use. It ensured extended-release for 24 h (73.6%) with the increased permeation flux (203.1 µg/cm2/hr) depicting its transdermal applicability [69]. Terbinafine is an allylamine and is derived synthetically. It restricts the ergosterol biosynthesis upon interfering with the squalene epoxidation, thus exhibiting a fungicidal action [70]. Elmataeeshy et al. (2017) attempted to achieve its systemic availability by developing its nanoemulgel. This gel showed superior efficacy and 3-fold higher transdermal permeation flux than its marketed counterpart (Lamisil®) intended for Candida infection. It presented a significant decrease in fungal load against Candida-infected rat skin compared to the other tested groups [42]. The nanoemulsion showed tremendous utility in delivering Sulconazole transdermally against candidiasis. The enhanced antifungal effectiveness of cotrimoxazole and miconazole against candidiasis and tinea pedis has been established by improving their aqueous solubilities. As per the Yang et al. report (2019), Sulconazole NE showed 1.7-fold and 3-fold higher rate of permeation than commercially available miconazole cream and Sulconazole-DMSO solution, respectively, assuming due to the smaller particle size (52.3 ± 3.8 nm). The zone of inhibition values presented by the Sulconazole NE against the Candida Albicans and Trichophyton rubrum was more significant than the two comparative preparations (miconazole cream and Sulconazole-DMSO solution), that is, 23.5 ± 2.4 and 20.4 ± 2.5 mm, respectively [24].